No title
BackgroundTo enable immunotherapy for ovarian cancers, precision targets for immune priming as well as patient stratification approaches are required. The tumor microenvironment in particularly the rare subtypes of low-grade serous, mucinous, clear cell and endometrioid ovarian cancer, remains poorly characterized, and these tumors have been largely ignored in the immuno-oncology setting.MethodsWe
